Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes-Reference-Cited by-同舟云学术

Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes

Published:2009-04 Issue:4 Volume:33 Page:547-550
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Tamburini J.,Elie C.,Park S.,Beyne-Rauzy O.,Gardembas M.,Berthou C.,Mahe B.,Sanhes L.,Stamatoullas A.,Vey N.,Aouba A.,Slama B.,Quesnel B.,Vekhoff A.,Sotto J.J.,Vassilief D.,Al-Nawakil C.,Fenaux P.,Dreyfus F.,Bouscary D.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference13 articles.

1. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model;Hellstrom-Lindberg;Br J Haematol,1997

2. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes;Musto;Br J Haematol,2005

3. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS);Rose;Br J Haematol,1995

4. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience;Park;Blood,2007

5. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies;Bouscary;Br J Haematol,2005

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improved Side Effect Profile of Alternate-Day Dosing of Lenalidomide;Cureus;2024-03-01

2. Erythropoiesis-Stimulating Agents in Low-Risk MDS;Myelodysplastic Syndromes;2018

3. Leki immunomodulujące – przełom w leczeniu nowotworów hematologicznych;Acta Haematologica Polonica;2013-10

4. Lenalidomide and thalidomide in the treatment of chronic pain;Expert Opinion on Drug Safety;2013-02-27

5. Immunomodulatory Drugs: New Options for the Treatment of Myelodysplastic Syndromes;Clinical Lymphoma Myeloma and Leukemia;2013-02